Merck & Co., Inc. Q2 2025 Earnings Recap

MRK Q2 2025 August 2, 2025

Get alerts when MRK reports next quarter

Merck & Co. reported Q2 2025 revenue of $15.8 billion, driven by strong performances in oncology and Animal Health, alongside robust new product contributions, marking a strategic growth phase for the company.

Earnings Per Share Beat

$2.13 vs $2.03 est.

+4.9% surprise

Revenue Miss

15806000000 vs 15864530543 est.

-0.4% surprise

Market Reaction

1-Day +1.16%

5-Day +0.21%

30-Day +5.25%

See MRK alongside your other holdings

Add to your portfolio — free

Key Takeaways

Achieved cumulative sales of $1 billion for WINREVAIR within just over a year of its approval.
Announced the acquisition of Verona Pharma, set to enhance capabilities in chronic obstructive pulmonary disease and cardiopulmonary treatments.
Positive clinical trial results from the oral PCSK9 inhibitor enlicitide and continued advancements in the oncology pipeline, including new approvals for KEYTRUDA.
Preparing for the launch of ENFLONSIA for RSV prevention, with FDA endorsement already secured.
Embarked on a multiyear optimization initiative to reallocate resources towards more promising growth drivers.

This summary was generated by AI from the official earnings call transcript and is provided for informational purposes only. It does not constitute financial advice. For the complete transcript and financial data, visit MRK on AllInvestView.

Next Q3 2025